SR One News

BY CATEGORY: ALL / NOTABLE / CLINICAL IMPACT / NEW INVESTMENTS / FINANCING AND PARTNERSHIPS / PEOPLE

BY YEAR: 2023 / 2022 / 2021 / 2020

Simcha Therapeutics announces first patient dosed in Ph1/2 study evaluating ST-067 in combination with KEYTRUDA® (Pembrolizumab)

Frances Benson 7/6/23 Frances Benson 7/6/23

Simcha Therapeutics announces first patient dosed in Ph1/2 study evaluating ST-067 in combination with KEYTRUDA® (Pembrolizumab)

Read More

FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia

Frances Benson 6/8/23 Frances Benson 6/8/23

FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia

Read More

HotSpot Therapeutics achieves first-in-human dosing with HST-1011, an investigational oral small molecule Allosteric Inhibitor of CBL-B

Frances Benson 4/11/23 Frances Benson 4/11/23

HotSpot Therapeutics achieves first-in-human dosing with HST-1011, an investigational oral small molecule Allosteric Inhibitor of CBL-B

Read More

HotSpot Therapeutics announces FDA clearance of IND application for HST-1011, an investigational small molecule allosteric inhibitor of CBL-B

Frances Benson 1/3/23 Frances Benson 1/3/23

HotSpot Therapeutics announces FDA clearance of IND application for HST-1011, an investigational small molecule allosteric inhibitor of CBL-B

Read More

Nimbus Therapeutics announces positive topline results for Ph2b clinical trial of allosteric TYK2 inhibitor

Frances Benson 11/30/22 Frances Benson 11/30/22

Nimbus Therapeutics announces positive topline results for Ph2b clinical trial of allosteric TYK2 inhibitor

Read More

ARS Pharmaceuticals announces FDA acceptance of NDA for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (type I) including anaphylaxis

Frances Benson 10/21/22 Frances Benson 10/21/22

ARS Pharmaceuticals announces FDA acceptance of NDA for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (type I) including anaphylaxis

Read More

CRISPR Therapeutics and Vertex presents new data on more patients with longer follow-up treated with exagamglogene autotemcel (exa-cel)

Frances Benson 6/11/22 Frances Benson 6/11/22

CRISPR Therapeutics and Vertex presents new data on more patients with longer follow-up treated with exagamglogene autotemcel (exa-cel)

Read More

$CRISPR Therapeutics presents positive results from its Ph1 COBALT™-LYM trial of CTX130™ in relapsed or refractory T cell malignancies$

Frances Benson 6/11/22 Frances Benson 6/11/22

CRISPR Therapeutics presents positive results from its Ph1 COBALT™-LYM trial of CTX130™ in relapsed or refractory T cell malignancies

Read More

Frances Benson 6/5/22 Frances Benson 6/5/22

eFFECTOR Therapeutics reports positive interim results in zotatifin (EFT226) Ph1/2 clinical trial

Read More

Arcellx presents continued robust long-term responses from its CART-DdBCMA Ph1 expansion trial

Frances Benson 6/3/22 Frances Benson 6/3/22

Arcellx presents continued robust long-term responses from its CART-DdBCMA Ph1 expansion trial

Read More

Arcellx announces dosing of first patient in its Ph1 clinical trial evaluating ACLX- 001, the first therapeutic in the dosable and controllable ARC- SparX Platform

Frances Benson 5/10/22 Frances Benson 5/10/22

Arcellx announces dosing of first patient in its Ph1 clinical trial evaluating ACLX- 001, the first therapeutic in the dosable and controllable ARC- SparX Platform

Read More

Nkarta Therapeutics announces positive preliminary dose finding data for two lead engineered natural killer cell programs

Frances Benson 4/25/22 Frances Benson 4/25/22

Nkarta Therapeutics announces positive preliminary dose finding data for two lead engineered natural killer cell programs

Read More

Nimbus Therapeutics presents clinical data from Ph1 study of oral allosteric TYK2 inhibitor at AAD Annual Meeting

Frances Benson 3/25/22 Frances Benson 3/25/22

Nimbus Therapeutics presents clinical data from Ph1 study of oral allosteric TYK2 inhibitor at AAD Annual Meeting

Read More

Second Genome nominates development candidate targeting PAI-1/2 for the treatment of inflammatory bowel disease

Frances Benson 2/10/22 Frances Benson 2/10/22

Second Genome nominates development candidate targeting PAI-1/2 for the treatment of inflammatory bowel disease

Read More

Decibel Therapeutics reports on continued progress of lead gene therapy product candidate DB-OTO

Frances Benson 2/9/22 Frances Benson 2/9/22

Decibel Therapeutics reports on continued progress of lead gene therapy product candidate DB-OTO

Read More

Nimbus Therapeutics shares update on discovery efforts in computational chemistry and expands leadership team

Frances Benson 2/2/22 Frances Benson 2/2/22

Nimbus Therapeutics shares update on discovery efforts in computational chemistry and expands leadership team

Read More

CRISPR Therapeutics and ViaCyte announce first patient dosed in Ph1 clinical trial

Frances Benson 2/2/22 Frances Benson 2/2/22

CRISPR Therapeutics and ViaCyte announce first patient dosed in Ph1 clinical trial

Read More

BioTheryX doses first patient in Ph1 study investigating lead protein degrader candidate BTX-1188

Frances Benson 1/26/22 Frances Benson 1/26/22

BioTheryX doses first patient in Ph1 study investigating lead protein degrader candidate BTX-1188

Read More

Turning Point Therapeutics announces FDA clearance of IND application for combination of Elzovantinib and Aumolertinib in EGFR mutant MET-amplified non-small cell lung cancer

Frances Benson 1/20/22 Frances Benson 1/20/22

Turning Point Therapeutics announces FDA clearance of IND application for combination of Elzovantinib and Aumolertinib in EGFR mutant MET-amplified non-small cell lung cancer

Read More

Palleon Pharmaceuticals announces IND clearance for its lead candidate E-602

Frances Benson 1/20/22 Frances Benson 1/20/22

Palleon Pharmaceuticals announces IND clearance for its lead candidate E-602

Read More